Eastern Capital LTD

Average Profitability
127%
Insider Buys Quantity
8
Insider Buys Sum
$28.5M
Insider Sells Quantity
6
Insider Sells Sum
$98.17M

Insider Activity of Eastern Capital LTD

The largest purchase of all time was on 2014-02-25 and amounted to 1000000 shares of Cytokinetics, Incorporated for $8M.

The largest sale of all time was on 2020-08-11 and amounted to 15864436 shares of iBio, Inc. for $46.33M.

Biography of Eastern Capital LTD

No biography is available at this moment.

2020-08-11SaleiBio, Inc.
IBIO
10 percent owner
15.86M
10.3338%
$2.92$46.33M-43.3%
2020-08-10SaleiBio, Inc.
IBIO
10 percent owner
7.26M
4.7429%
$3.91$28.43M-57.45%
2020-08-07SaleiBio, Inc.
IBIO
10 percent owner
1.36M
0.8401%
$3.83$5.19M-58.42%
2020-08-06SaleiBio, Inc.
IBIO
10 percent owner
2.77M
1.7544%
$4.18$11.57M-61.08%
2020-08-05SaleiBio, Inc.
IBIO
10 percent owner
900,000
0.5628%
$4.46$4.01M-64.01%
2020-08-04SaleiBio, Inc.
IBIO
10 percent owner
600,000
0.3697%
$4.39$2.64M-64.01%
2018-07-12PurchaseiBio, Inc.
IBIO
10 percent owner
2.2M
13.5602%
$0.90$1.98M0%
2018-06-26PurchaseiBio, Inc.
IBIO
10 percent owner
1.69M
9.4071%
$0.90$1.52M-8.89%
2018-05-14PurchaseMarker Therapeutics, Inc.
MRKR
10 percent owner
2.6M
17.57%
$2.40$6.24M+127%
2017-11-30PurchaseiBio, Inc.
IBIO
10 percent owner
12M
13.3275%
$0.20$2.4M-26.32%
2016-04-07PurchaseiBio, Inc.
IBIO
10 percent owner
6.5M
7.7744%
$0.62$4.04M-6.9%
2016-01-25PurchaseiBio, Inc.
IBIO
10 percent owner
3.5M
5.0045%
$0.62$2.18M+7.41%
2014-02-25PurchaseCytokinetics, Incorporated
CYTK
10 percent owner
1M
2.4109%
$8.00$8M-53.78%
2013-04-26PurchaseiBio, Inc.
IBIO
10 percent owner
4.46M
9.8305%
$0.48$2.14M+2.27%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.